ChromaDex banner
ChromaDex banner

Investment

Rejuveron appoints anti-aging pioneer to Scientific Advisory Board

Swiss biotech Rejuveron announces the appointment of biomedical gerontologist, Dr Aubrey de Grey. Rejuveron Life Sciences AG, a Zürich-based biotechnology company developing technologies for healthy...

R42 launches $14 million Longevity fund

We speak exclusively to Ronjon Nag about his first fund, targeting seed investments in Longevity AI and biotech. The world of Longevity-specific investment funds just...

Clene goes for gold, and goes public

Company targeting neurodegenerative disease with gold nanocatalyst technology goes public; multiple human trials ongoing for MS, Parkinson's and ALS. Salt Lake City biopharma company Clene...

Longevity companies to watch in 2021

As the world enters the new year with a vaccine and an increased focus on geroprotection, there’s much to look forward to. Research from the...

A year in Longevity: investment perspectives

New funds, switching focus to Longevity, Silicon Valley blue-bloods and preparing for IPO. Over the past year, we’ve had the pleasure of speaking with some...

LyGenesis’ FDA phase 2a clearance and $11m funding boost

Double bubble for biotech LyGenesis as it announces trial of its cell therapy for patients with end-stage liver disease, and closure of $11m convertible...

A year in Longevity: different perspectives

Looking for anti-aging solutions in some unusual places. 2020 has seen Longevity.Technology covering a variety of news in the Longevity sector, from discoveries in the...

A year in Longevity: founders’ perspectives

Speaking to the innovators behind some of Longevity’s most exciting companies. Continuing our look back at some of the highlights of 2020, we thought we’d...

A year in Longevity: science perspectives

Longevity leaders on the key issues facing our sector. Over the past year, we’ve had the pleasure of speaking to some of the Longevity sector’s...

VC and drug developer scale-up their incubator model

Collaboration set to establish new ventures for drug discovery and development and advance UCSF discoveries to patients. Autobahn Labs has announced a strategic collaboration with...

Human Longevity and the Final Frontier

World’s first Space and Longevity VC fund prepares for launch. A new rolling investment fund is gearing up to make its first Longevity investments in...

Regent Pacific completes acquisition of Deep Longevity

The Hong Kong group has acquired the Longevity AI and aging clock specialist Deep Longevity. In a move that cements their expansion into the emerging...

Sigilon IPO raises $145m to address chronic diseases

Sigilon boosts its human cell therapeutics pipeline through IPO. Sigilon Therapeutics, Inc, a biotech seeking to develop functional cures for chronic diseases through its Shielded...

BioAge CEO: “It’s all about the data.”

BioAge's Kristen Fortney explains how focusing on human data will see two age-targeting drugs head to the clinic next year. Yesterday, the world again sat...

Silicon Valley is waking up to Longevity and senolytics

Silicon Valley's Rubedo Life Sciences closes $12m seed round for proprietary drug discovery platform that targets senolytics. Following-on from BioAge's funding announcement, another biotech start-up...

BioAge lands $90 million; gears up for clinical trials in 2021

Company also appoints Chief Medical Officer as it prepares to enter the clinic with two Phase 2-ready therapeutic compounds that target aging pathways. Longevity biotech...

Master Investor Show: come and meet the team

The Master Investor Show is the UK’s leading event for private investors. This year, for obvious reasons, it’s going virtual and we'll be there...

Healthtech start-up reaches $120m revenue in under four years

UK start-up Cera is one of Europe’s fastest-growing businesses with $120m in revenue. Cera is a technology-enabled home care provider that uses digital and data...

Neurotech2020 – a clear head for neurotech, research and investment

Tomorrow's dreams today ... well, next week – it's Neurotech2020. Neurotech2020 – the digital congress for neurotechnology innovation and growth – is coming to (your...

Biotech Elevian announces $15m equity financing

The anti-aging company looks to the clinic with Prime Movers Lab leading the round. Massachusets-based Elevian announced this week that it had closed $15 million equity...
ChromaDex TruNiagen
lumen

Latest articles